CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. ・The study ...

Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec. 10, 2025 ...

RBC Capital notes that Corbus Pharmaceuticals (CRBP) has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse ...

Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

Here at A3, we believe in equal opportunity. We recognize that saying we have an addiction problem is not the same as saying we have a drug use problem and that just because some people abuse ...

Nearly half of the world’s population suffers from allergic rhinitis, meaning that when they inhale allergens from the air, IgE becomes activated and induces paroxysmal sneezing, runny nose and nasal ...